BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-72. [PMID: 18594873 DOI: 10.1007/s00467-008-0872-4] [Cited by in Crossref: 135] [Cited by in F6Publishing: 109] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Johnson S, Waters A. Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome? Immunobiology 2012;217:235-43. [PMID: 21852019 DOI: 10.1016/j.imbio.2011.07.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
2 Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) 2014;1:52. [PMID: 25593925 DOI: 10.3389/fmed.2014.00052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
3 Coppo R, Bonaudo R, Peruzzi RL, Amore A, Brunati A, Romagnoli R, Salizzoni M, Galbusera M, Gotti E, Daina E, Noris M, Remuzzi G. Liver transplantation for aHUS: still needed in the eculizumab era? Pediatr Nephrol. 2016;31:759-768. [PMID: 26604087 DOI: 10.1007/s00467-015-3278-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
4 Ntuli V, Njage PMK, Bonilauri P, Serraino A, Buys EM. Quantitative Risk Assessment of Hemolytic Uremic Syndrome Associated with Consumption of Bulk Milk Sold Directly from Producer to Consumer in South Africa. Journal of Food Protection 2018;81:472-81. [DOI: 10.4315/0362-028x.jfp-17-199] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
5 Jacquinet S, De Rauw K, Pierard D, Godefroid N, Collard L, Van Hoeck K, Sabbe M. Haemolytic uremic syndrome surveillance in children less than 15 years in Belgium, 2009-2015. Arch Public Health 2018;76:41. [PMID: 30128150 DOI: 10.1186/s13690-018-0289-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
6 Blasco Pelicano M, Rodríguez de Córdoba S, Campistol Plana JM. Síndrome hemolítico urémico atípico. Medicina Clínica 2015;145:438-45. [DOI: 10.1016/j.medcli.2014.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Karpman D, Tati R. Complement activation in thrombotic microangiopathy. Hamostaseologie 2013;33:96-104. [PMID: 23411690 DOI: 10.5482/HAMO-12-12-0025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Orth D, Ehrlenbach S, Brockmeyer J, Khan AB, Huber G, Karch H, Sarg B, Lindner H, Würzner R. EspP, a serine protease of enterohemorrhagic Escherichia coli, impairs complement activation by cleaving complement factors C3/C3b and C5. Infect Immun 2010;78:4294-301. [PMID: 20643852 DOI: 10.1128/IAI.00488-10] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
9 Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:1312-6. [PMID: 19556379 DOI: 10.2215/CJN.01090209] [Cited by in Crossref: 113] [Cited by in F6Publishing: 49] [Article Influence: 8.7] [Reference Citation Analysis]
10 Lee MD, Tzen CY, Lin CC, Huang FY, Liu HC, Tsai JD. Hemolytic uremic syndrome caused by enteroviral infection. Pediatr Neonatol 2013;54:207-10. [PMID: 23597514 DOI: 10.1016/j.pedneo.2012.10.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016;89:701-11. [PMID: 26880462 DOI: 10.1016/j.kint.2015.11.026] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 23.5] [Reference Citation Analysis]
12 Sauvètre G, Grange S, Froissart A, Veyradier A, Coppo P, Benhamou Y. La révolution des anticorps monoclonaux dans la prise en charge des microangiopathies thrombotiques. La Revue de Médecine Interne 2015;36:328-38. [DOI: 10.1016/j.revmed.2014.10.364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
13 Iorember F, Nayak A. Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring. Pediatr Nephrol 2021;36:1365-75. [PMID: 32529325 DOI: 10.1007/s00467-020-04652-x] [Reference Citation Analysis]
14 Noris M, Remuzzi G. Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Seminars in Nephrology 2010;30:395-408. [DOI: 10.1016/j.semnephrol.2010.06.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
15 Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis. 2012;59:707-710. [PMID: 22196848 DOI: 10.1053/j.ajkd.2011.11.027] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
16 Bouw MC, Dors N, van Ommen H, Ramakers-van Woerden NL. Thrombotic thrombocytopenic purpura in childhood: Thrombotic Thrombocytopenic Purpura in Childhood. Pediatr Blood Cancer 2009;53:537-42. [DOI: 10.1002/pbc.22094] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
17 Haller W, Milford DV, Goodship TH, Sharif K, Mirza DF, McKiernan PJ. Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H. Am J Transplant 2010;10:2142-7. [PMID: 20738267 DOI: 10.1111/j.1600-6143.2010.03228.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lesher AM, Song WC. Review: Complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) 2010;15:663-75. [PMID: 21040161 DOI: 10.1111/j.1440-1797.2010.01373.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
19 Eisenhut M. Pathophysiology of disinhibition of complement activation. Pediatr Crit Care Med 2010;11:631-2. [PMID: 20823737 DOI: 10.1097/PCC.0b013e3181d8e19b] [Reference Citation Analysis]
20 Fraga-Rodriguez GM, Brió-Sanagustin S, Turón-Viñas E, Dixon BP, Carreras-González E. Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Rep 2017;2017:bcr-2016-219065. [PMID: 28446488 DOI: 10.1136/bcr-2016-219065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
21 Loirat C, Macher MA, Elmaleh-Berges M, Kwon T, Deschênes G, Goodship TH, Majoie C, Davin JC, Blanc R, Savatovsky J, Moret J, Fremeaux-Bacchi V. Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol Dial Transplant 2010;25:3421-5. [PMID: 20530807 DOI: 10.1093/ndt/gfq319] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
22 Crovetto F, Borsa N, Acaia B, Nishimura C, Frees K, Smith RJH, Peyvandi F, Palla R, Cugno M, Tedeschi S, Castorina P, Somigliana E, Ardissino G, Fedele L. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. The Journal of Maternal-Fetal & Neonatal Medicine 2012;25:2322-5. [DOI: 10.3109/14767058.2012.694923] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
23 Naina HV, Gertz MA, Elliott MA. Thrombotic microangiopathy during peripheral blood stem cell mobilization. J Clin Apher 2009;24:259-61. [PMID: 19877288 DOI: 10.1002/jca.20216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
24 Rosove MH. Thrombotic microangiopathies. Seminars in Arthritis and Rheumatism 2014;43:797-805. [DOI: 10.1016/j.semarthrit.2013.11.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
25 Schifferli A, von Vigier RO, Fontana M, Spartà G, Schmid H, Bianchetti MG, Rudin C; Swiss Pediatric Surveillance Unit. Hemolytic-uremic syndrome in Switzerland: a nationwide surveillance 1997-2003. Eur J Pediatr 2010;169:591-8. [PMID: 19830454 DOI: 10.1007/s00431-009-1079-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
26 Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 2011;26:2085-8. [DOI: 10.1007/s00467-011-1989-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
27 Nester CM. Multifaceted hemolytic uremic syndrome in pediatrics. Blood Purif 2013;35:86-92. [PMID: 23343552 DOI: 10.1159/000346486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Cho H. Complement regulation: physiology and disease relevance. Korean J Pediatr 2015;58:239-44. [PMID: 26300937 DOI: 10.3345/kjp.2015.58.7.239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
29 Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol 2013; 2(3): 56-76 [PMID: 24255888 DOI: 10.5527/wjn.v2.i3.56] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
30 Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. [PMID: 24526222 DOI: 10.1007/s00281-014-0416-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
31 Sinibaldi S, Guzzo I, Piras R, Bresin E, Emma F, Dello Strologo L. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Pediatr Transplant. 2013;17:E177-E181. [PMID: 24118826 DOI: 10.1111/petr.12151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
32 Kwon T, Belot A, Ranchin B, Baudouin V, Fremeaux-Bacchi V, Dragon-Durey MA, Cochat P, Loirat C. Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases. Nephrol Dial Transplant 2009;24:2752-4. [PMID: 19376828 DOI: 10.1093/ndt/gfp166] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
33 Vitkauskaitė M, Vinikovas A, Miglinas M, Rimševičius L, Čerkauskaitė A, Mačionienė E, Ašakienė E. Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5573] [Reference Citation Analysis]
34 Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med. 2012;41:e115-e135. [PMID: 22284541 DOI: 10.1016/j.lpm.2011.11.013] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
35 Zhou D, Tan Y, Liu X, Tang L, Wang H, Shen J, Wang W, Zhuang L, Tao J, Su J, Gong T, Liu X, Liang P, Yu F, Zhao M. Patient-specific iPSC-derived endothelial cells reveal aberrant p38 MAPK signaling in atypical hemolytic uremic syndrome. Stem Cell Reports 2021:S2213-6711(21)00377-5. [PMID: 34388364 DOI: 10.1016/j.stemcr.2021.07.011] [Reference Citation Analysis]
36 Karpman D, Ståhl AL, Arvidsson I, Johansson K, Loos S, Tati R, Békássy Z, Kristoffersson AC, Mossberg M, Kahn R. Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions. Adv Exp Med Biol 2015;865:19-42. [PMID: 26306441 DOI: 10.1007/978-3-319-18603-0_2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
37 Ma M, Mazumder S, Kwak H, Adams M, Gregory M. Case Report: Acute Thrombotic Microangiopathy in a Patient with STING-Associated Vasculopathy with Onset in Infancy (SAVI). J Clin Immunol 2020;40:1111-5. [PMID: 32860170 DOI: 10.1007/s10875-020-00850-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
38 Glassock RJ, Bargman JM, Palmer BF, Samaniego M, Fervenza FC. Nephrology Quiz and Questionnaire: 2009. CJASN 2010;5:1141-60. [DOI: 10.2215/cjn.00540110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Basnayake BMDB, Wazil AWM, Nanayakkara N, Samarakoon SMDK, Senavirathne EMSK, Thangarajah BUEWDR, Karunasena N, Mahanama RMBSS. Atypical hemolytic uremic syndrome: a case report. J Med Case Rep 2020;14:11. [PMID: 31928535 DOI: 10.1186/s13256-019-2334-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Fakhouri F, Frémeaux-bacchi V, Noël L, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010;6:494-9. [DOI: 10.1038/nrneph.2010.85] [Cited by in Crossref: 255] [Cited by in F6Publishing: 200] [Article Influence: 21.3] [Reference Citation Analysis]
41 Cheong HI. Trombotic microangiopathy: can liver-kidney transplantation cure aHUS? Nat Rev Nephrol 2009;5:556-7. [PMID: 19776774 DOI: 10.1038/nrneph.2009.148] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009;27:621-68. [PMID: 19302049 DOI: 10.1146/annurev.immunol.25.022106.141627] [Cited by in Crossref: 730] [Cited by in F6Publishing: 618] [Article Influence: 56.2] [Reference Citation Analysis]
43 Ståhl AL, Kristoffersson A, Olin AI, Olsson ML, Roodhooft AM, Proesmans W, Karpman D. A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome. Mol Immunol 2009;46:2236-43. [PMID: 19446882 DOI: 10.1016/j.molimm.2009.04.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
44 Reusz G, Szabó A, Réti M, Györke Z, Szilágyi Á, Farkas P, Prohászka Z. Diagnosis and Classification of Hemolytic Uremic Syndrome: The Hungarian Experience. Transplantation Proceedings 2011;43:1247-9. [DOI: 10.1016/j.transproceed.2011.03.071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
45 Sartz L, Olin AI, Kristoffersson AC, Ståhl AL, Johansson ME, Westman K, Fremeaux-Bacchi V, Nilsson-Ekdahl K, Karpman D. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol 2012;188:2030-7. [PMID: 22250080 DOI: 10.4049/jimmunol.1100319] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
46 Tran H, Chaudhuri A, Concepcion W, Grimm PC. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation. Pediatr Nephrol 2014;29:477-80. [PMID: 24221349 DOI: 10.1007/s00467-013-2630-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
47 Badiola J, Navarrete-Navarrete N, Sabio JM. Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review. Rheumatol Int 2019;39:359-65. [PMID: 30554307 DOI: 10.1007/s00296-018-4228-5] [Reference Citation Analysis]
48 Pelras S, Delmas Y, Lamireau D, Villega F, Nolent P, Ryman A, Llanas B, Brissaud O, Harambat J. Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome. Pediatr Nephrol 2011;26:631-5. [PMID: 21161282 DOI: 10.1007/s00467-010-1721-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
49 Choi HS, Cheong HI, Kim NK, Oh D, Park HW. ADAMTS13 gene mutations in children with hemolytic uremic syndrome. Yonsei Med J 2011;52:530-4. [PMID: 21488199 DOI: 10.3349/ymj.2011.52.3.530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
50 Carter CE, Benador NM. Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. Pediatr Nephrol 2014;29:35-50. [PMID: 23812351 DOI: 10.1007/s00467-013-2479-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
51 Gilardin L, Malak S, Schoindre Y, Galicier L, Veyradier A, Coppo P. Purpura thrombotique thrombocytopénique et autres syndromes de microangiopathie thrombotique au cours de l’infection par le virus de l’immunodéficience humaine. La Revue de Médecine Interne 2012;33:259-64. [DOI: 10.1016/j.revmed.2011.11.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
52 Albertazzi V, Bonucchi D, De Amicis S, Americo C, Ghiandai G, Cappelli G. A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: case report. Transplant Proc 2010;42:1352-4. [PMID: 20534299 DOI: 10.1016/j.transproceed.2010.03.048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
53 Thurman JM. Therapeutic regulation of complement in patients with renal disease - where is the promise? Clin Nephrol 2012;77:413-23. [PMID: 22551888 DOI: 10.5414/cn107220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
54 Zipfel PF, Mache C, Müller D, Licht C, Wigger M, Skerka C; for the European DEAP-HUS Study Group. DEAP-HUS: Deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol 2010;25:2009-19. [DOI: 10.1007/s00467-010-1446-9] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 4.9] [Reference Citation Analysis]
55 Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol 2011;3:5-12. [PMID: 22287852 DOI: 10.2147/CPAA.S17904] [Cited by in Crossref: 7] [Cited by in F6Publishing: 24] [Article Influence: 0.6] [Reference Citation Analysis]
56 Antwi-Baffour S, Kyeremeh R, Adjei JK, Aryeh C, Kpentey G. The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation. Auto Immun Highlights 2016;7:6. [PMID: 26935316 DOI: 10.1007/s13317-016-0078-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
57 Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859. [PMID: 20595690 DOI: 10.2215/cjn.02210310] [Cited by in Crossref: 584] [Cited by in F6Publishing: 274] [Article Influence: 48.7] [Reference Citation Analysis]
58 Tati R, Kristoffersson AC, Ståhl AL, Rebetz J, Wang L, Licht C, Motto D, Karpman D. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 2013;191:2184-93. [PMID: 23878316 DOI: 10.4049/jimmunol.1301221] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
59 Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Frémeaux-Bacchi V, Niaudet P. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant. 2012;12:1938-1944. [PMID: 22494769 DOI: 10.1111/j.1600-6143.2012.04051.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
60 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
61 Bento D, Mapril J, Rocha C, Marchbank KJ, Kavanagh D, Barge D, Strain L, Goodship TH, Meneses-Oliveira C. Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1). Ren Fail 2010;32:753-6. [PMID: 20540647 DOI: 10.3109/0886022X.2010.486491] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
62 Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc. 2012;44:3037-3040. [PMID: 23195022 DOI: 10.1016/j.transproceed.2012.07.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
63 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015;35:421-47. [DOI: 10.1016/j.nefroe.2015.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
64 Wilson C, Torpey N, Jaques B, Strain L, Talbot D, Manas D, Goodship T. Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H. Am J Kidney Dis 2011;58:109-12. [PMID: 21601332 DOI: 10.1053/j.ajkd.2011.04.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
65 Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 2014;10:174-80. [DOI: 10.1038/nrneph.2013.280] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
66 Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C. Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 2014;29:841-51. [DOI: 10.1007/s00467-013-2654-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
67 Kościelska-Kasprzak K, Bartoszek D, Myszka M, Zabińska M, Klinger M. The complement cascade and renal disease. Arch Immunol Ther Exp (Warsz) 2014;62:47-57. [PMID: 24030732 DOI: 10.1007/s00005-013-0254-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
68 Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, Geary DF, Zipfel PF, Kahr WH. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood 2009;114:4538-45. [PMID: 19704120 DOI: 10.1182/blood-2009-03-205096] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
69 Ávila A, Vizcaíno B, Molina P, Gavela E, Perez-Ebri M, Pallardó L. Remission of aHUS neurological damage with eculizumab. Clin Kidney J 2015;8:232-6. [PMID: 25815183 DOI: 10.1093/ckj/sfu144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
70 Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
71 Mele C, Lemaire M, Iatropoulos P, Piras R, Bresin E, Bettoni S, Bick D, Helbling D, Veith R, Valoti E, Donadelli R, Murer L, Neunhäuserer M, Breno M, Frémeaux-Bacchi V, Lifton R, Remuzzi G, Noris M. Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. Clin J Am Soc Nephrol 2015;10:1011-9. [PMID: 25854283 DOI: 10.2215/CJN.08520814] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
72 Yenerel MN. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol 2014;31:216-25. [PMID: 25319590 DOI: 10.4274/tjh.2013.0374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
73 Shin HS, Nester CM, Dixon BP. Comorbidity of inflammatory bowel disease with atypical hemolytic uremic syndrome in pediatric patients. Clin Nephrol Case Stud 2019;7:35-40. [PMID: 31312592 DOI: 10.5414/CNCS109511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Udagawa T, Motoyoshi Y, Matsumura Y, Takei A, Ariji S, Ito E, Chiga M, Nagasawa M, Morio T, Mizutani S. Effect of eculizumab and recombinant human soluble thrombomodulin combination therapy in a 7-year-old girl with atypical hemolytic uremic syndrome due to anti-factor H autoantibodies. CEN Case Rep 2014;3:110-7. [PMID: 28509254 DOI: 10.1007/s13730-013-0097-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
75 Canpolat N. Hemolytic uremic syndrome. Turk Pediatri Ars 2015;50:73-82. [PMID: 26265890 DOI: 10.5152/tpa.2015.2297] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
76 Sartain SE, Turner NA, Moake JL. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. J Biol Chem 2018;293:7195-208. [PMID: 29555686 DOI: 10.1074/jbc.RA118.002639] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
77 Andries G, Karass M, Yandrapalli S, Linder K, Liu D, Nelson J, Pawar R, Chugh S. Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab. Exp Hematol Oncol 2017;6:4. [PMID: 28101432 DOI: 10.1186/s40164-017-0064-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
78 Chung C. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab. Ann Pharmacother 2021;55:330-43. [PMID: 32715723 DOI: 10.1177/1060028020941852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology 2012;2012:617-25. [DOI: 10.1182/asheducation.v2012.1.617.3798924] [Cited by in Crossref: 66] [Article Influence: 6.6] [Reference Citation Analysis]
80 Caltik A, Akyüz SG, Erdogan O, Demircin G. Hemolytic uremic syndrome triggered with a new pandemic virus: influenza A (H1N1). Pediatr Nephrol 2011;26:147-8. [PMID: 20878189 DOI: 10.1007/s00467-010-1649-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
81 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35:421-47. [PMID: 26456110 DOI: 10.1016/j.nefro.2015.07.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis]
82 Funato M, Uemura O, Ushijima K, Ohnishi H, Orii K, Kato Z, Yamakawa S, Nagai T, Ohara O, Kaneko H. A complement factor B mutation in a large kindred with atypical hemolytic uremic syndrome. J Clin Immunol. 2014;34:691-695. [PMID: 24906628 DOI: 10.1007/s10875-014-0058-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
83 Benz K, Amann K. Thrombotic microangiopathy: new insights. Curr Opin Nephrol Hypertens 2010;19:242-7. [PMID: 20186056 DOI: 10.1097/MNH.0b013e3283378f25] [Cited by in Crossref: 62] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
84 Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. American Journal of Kidney Diseases 2016;68:84-93. [DOI: 10.1053/j.ajkd.2015.12.034] [Cited by in Crossref: 144] [Cited by in F6Publishing: 124] [Article Influence: 24.0] [Reference Citation Analysis]
85 Taylor CM, Machin S, Wigmore SJ, Goodship TH; working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010;148:37-47. [PMID: 19821824 DOI: 10.1111/j.1365-2141.2009.07916.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 113] [Article Influence: 11.5] [Reference Citation Analysis]
86 Obut F, Kasinath V, Abdi R. Post-bone marrow transplant thrombotic microangiopathy. Bone Marrow Transplant 2016;51:891-7. [DOI: 10.1038/bmt.2016.61] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
87 De S, Waters AM, Segal AO, Trautmann A, Harvey EA, Licht C. Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options. Pediatr Nephrol 2010;25:97-104. [PMID: 19856002 DOI: 10.1007/s00467-009-1306-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
88 Quiviger S, Fléchelles O, Cécile W, Hatchuel Y. Syndrome hémolytique et urémique secondaire à Streptococcus pneumoniae de sérotype 3. Archives de Pédiatrie 2012;19:599-602. [DOI: 10.1016/j.arcped.2012.03.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
89 Janssen van Doorn K, Dirinck E, Verpooten GA, Couttenye MM. Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome. Clin Kidney J 2013;6:216-9. [PMID: 25006455 DOI: 10.1093/ckj/sfs190] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
90 Nester CM, Brophy PD. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. Curr Opin Pediatr. 2013;25:225-231. [PMID: 23486421 DOI: 10.1097/mop.0b013e32835df4a3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
91 Webster K, Schnitzler E. Hemolytic uremic syndrome. Handb Clin Neurol 2014;120:1113-23. [PMID: 24365375 DOI: 10.1016/B978-0-7020-4087-0.00075-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
92 Shatzel JJ, Taylor JA. Syndromes of Thrombotic Microangiopathy. Med Clin North Am 2017;101:395-415. [PMID: 28189178 DOI: 10.1016/j.mcna.2016.09.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
93 Fagiuoli S, Daina E, D'Antiga L, Colledan M, Remuzzi G. Monogenic diseases that can be cured by liver transplantation. J Hepatol. 2013;59:595-612. [PMID: 23578885 DOI: 10.1016/j.jhep.2013.04.004] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 9.0] [Reference Citation Analysis]
94 Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365:8-26. [PMID: 21215749 DOI: 10.1016/j.jim.2010.12.020] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
95 Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 2014;123:2478-84. [PMID: 24599547 DOI: 10.1182/blood-2013-11-516237] [Cited by in Crossref: 86] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
96 Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013;24:475-486. [PMID: 23431077 DOI: 10.1681/asn.2012090884] [Cited by in Crossref: 231] [Cited by in F6Publishing: 110] [Article Influence: 25.7] [Reference Citation Analysis]
97 Neild GH, Santos C, Lopes D, Gomes A, Ventura A, Tente D, Seabra J. Cutaneous involvement in haemolytic uraemic syndrome. Clin Kidney J 2013;6:655-6. [PMID: 26120461 DOI: 10.1093/ckj/sft114] [Reference Citation Analysis]
98 Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57. [PMID: 20556434 DOI: 10.1007/s00467-010-1556-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
99 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
100 Rosales A, Riedl M, Zimmerhackl LB. Thrombotic microangiopathy: atypical HUS: current diagnostic and therapeutic approaches. Nat Rev Nephrol 2010;6:504-6. [PMID: 20736981 DOI: 10.1038/nrneph.2010.98] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
101 Medhioub Kaaniche F, Chaari A, Bacouch N, Bahloul M, Bouaziz M. Syndrome hémolytique et urémique de l’adulte jeune par trouble du métabolisme de la cobalamine : à propos d’un cas. La Presse Médicale 2016;45:148-50. [DOI: 10.1016/j.lpm.2015.10.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
102 Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. [PMID: 21902819 DOI: 10.1186/1750-1172-6-60] [Cited by in Crossref: 375] [Cited by in F6Publishing: 304] [Article Influence: 34.1] [Reference Citation Analysis]
103 Trachtman H. Introduction: education teaching article series on hemolytic uremic syndrome. Pediatr Nephrol 2008;23:1423-4. [PMID: 18535846 DOI: 10.1007/s00467-008-0822-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathologie Biologie 2015;63:136-43. [DOI: 10.1016/j.patbio.2015.03.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
105 Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013;61:289-299. [PMID: 23141475 DOI: 10.1053/j.ajkd.2012.07.028] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis]
106 Tawadrous H, Maga T, Sharma J, Kupferman J, Smith RJ, Schoeneman M. A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome. Pediatr Nephrol 2010;25:947-51. [PMID: 20108004 DOI: 10.1007/s00467-009-1415-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
107 Jung S, Kang E, Ki C, Kim D, Paik K, Chang YS. Successful therapeutic plasma exchange in a 3.2-kg body weight neonate with atypical hemolytic uremic syndrome. J Clin Apheresis 2011;26:162-5. [DOI: 10.1002/jca.20283] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
108 Li J, Long D, Wu S, Wu X, Wei B, Chen D, Shao Y, Wang H, Cui L, Chen X, Yu L. Association of CFH polymorphism with susceptibility to sepsis caused by Pseudomonas aeruginosa in Chinese Han populations: A multi-center study. Gene 2020;722:144127. [PMID: 31525397 DOI: 10.1016/j.gene.2019.144127] [Reference Citation Analysis]
109 Welch TR, Blystone LW. Renal disease associated with inherited disorders of the complement system. Pediatr Nephrol 2009;24:1439-44. [DOI: 10.1007/s00467-008-1027-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
110 Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M, Zipfel PF, Józsi M. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2010;25:136-44. [PMID: 19666655 DOI: 10.1093/ndt/gfp388] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
111 Nikolajeva O, Worth A, Hague R, Martinez-Alier N, Smart J, Adams S, Davies EG, Gaspar HB. Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome. J Clin Immunol 2015;35:366-72. [PMID: 25875700 DOI: 10.1007/s10875-015-0158-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
112 Martin SM, Balestracci A, Puyol I, Toledo I, Cao G, Arizeta G. Uncommon Presentation of Atypical Hemolytic Uremic Syndrome: A Case Report. Indian J Nephrol 2021;31:478-81. [PMID: 34880559 DOI: 10.4103/ijn.IJN_271_20] [Reference Citation Analysis]
113 Schönauer R, Seidel A, Grohmann M, Lindner TH, Bergmann C, Halbritter J. Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome. Front Genet 2019;10:465. [PMID: 31156713 DOI: 10.3389/fgene.2019.00465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2011;6:1488-1494. [PMID: 21617085 DOI: 10.2215/cjn.10181110] [Cited by in Crossref: 91] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
115 Caillaud C, Zaloszyc A, Licht C, Pichault V, Frémeaux-Bacchi V, Fischbach M. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 2016;31:157-61. [PMID: 26399238 DOI: 10.1007/s00467-015-3207-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
116 Joseph C, Gattineni J. Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr 2013;25:209-15. [PMID: 23399570 DOI: 10.1097/MOP.0b013e32835df48a] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
117 Büyükçelik M, Keskin M, Keskin Ö, Bay A, Kılıç BD, Kor Y, Kılınç MA, Balat A. Autoimmune polyglandular syndrome type 3c with ectodermal dysplasia, immune deficiency and hemolytic-uremic syndrome. J Clin Res Pediatr Endocrinol 2014;6:47-50. [PMID: 24637310 DOI: 10.4274/Jcrpe.1128] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Soraru J, Isbel N, Wong G, Coates PT, Mantha M, Abraham A, Juneja R, Hsu D, Brown F, Bose B, Mudge D, Carroll R, Kausman J, Hughes P, Barbour T, Durkan A, Mount P, Lee D, Larkins N, Ranganathan D, Lim WH. Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry. Nephrology (Carlton) 2020;25:683-90. [PMID: 32378251 DOI: 10.1111/nep.13722] [Reference Citation Analysis]